Trifluoromethyl group as a pharmacophore:: Effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand

被引:104
作者
Betageri, R
Zhang, Y
Zindell, RM
Kuzmich, D
Kirrane, TM
Bentzien, J
Cardozo, M
Capolino, AJ
Fadra, TN
Nelson, RM
Paw, Z
Shih, DT
Shih, CK
Zuvela-Jelaska, L
Nabozny, G
Thomson, DS
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Dept Med Chem, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharmaceut Inc, Dept Cardiovasc Dis, Ridgefield, CT 06877 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Dept Immunol & Inflammat, Ridgefield, CT 06877 USA
[4] Johnson & Johnson Pharmaceut Res & Dev LLC, Drug Discovery Div, Raritan, NJ 08869 USA
[5] Amgen San Francisco, Dept Biol Struct, San Francisco, CA 94080 USA
关键词
glucocorticoid receptor; glucocorticoid receptor ligand; trifluoromethyl group; pharmacophore; glucocorticoid receptor antagonist; RU486; Helix; 12;
D O I
10.1016/j.bmcl.2005.07.025
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Compound 1, a potent glucocorticoid receptor ligand, contains a quaternary carbon bearing trifluoromethyl and hydroxyl groups. This paper describes the effect of replacing the trifluoromethyl group on binding and agonist activity of the GR ligand 1. The results illustrate that replacing the CF3 group with a cyclohexylmethyl or benzyl group maintains the GR binding potency. These substitutions alter the functional behavior of the GR ligands from agonists to antagonists. Docking studies suggest that the benzyl analog 19 binds in a similar fashion as the GR antagonist, RU486. The central benzyl group of 19 and the C-11 dimethylaniline moiety of RU486 overlay. Binding of compound 19 is believed to force helix 12 to adopt an open conformation and this leads to the antagonist properties of the non-CF3 ligands carrying a large group at the center of the molecule. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4761 / 4769
页数:9
相关论文
共 42 条
  • [11] Cohen E. M., 1973, Analytical profiles of drug substances. 2, P163, DOI DOI 10.1016/S0099-5428(08)60039-8
  • [12] Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases
    Eggert, M
    Schulz, M
    Neeck, G
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 77 (4-5) : 185 - 191
  • [13] Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators
    Elmore, SW
    Pratt, JK
    Coghlan, MJ
    Mao, Y
    Green, BE
    Anderson, DD
    Stashko, MA
    Lin, CW
    Falls, D
    Nakane, M
    Miller, L
    Tyree, CM
    Miner, JN
    Lane, B
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (07) : 1721 - 1727
  • [14] Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice
    Friedman, JE
    Sun, Y
    Ishizuka, T
    Farrell, CJ
    McCormack, SE
    Herron, LM
    Hakimi, P
    Lechner, P
    Yun, JS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) : 31475 - 31481
  • [15] Corticosteroids: the mainstay in asthma therapy
    Gupta, R
    Jindal, DP
    Kumar, G
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (24) : 6331 - 6342
  • [16] A DISTINCT MODULATING DOMAIN IN GLUCOCORTICOID RECEPTOR MONOMERS IN THE REPRESSION OF ACTIVITY OF THE TRANSCRIPTION FACTOR AP-1
    HECK, S
    KULLMANN, M
    GAST, A
    PONTA, H
    RAHMSDORF, HJ
    HERRLICH, P
    CATO, ACB
    [J]. EMBO JOURNAL, 1994, 13 (17) : 4087 - 4095
  • [17] Putting the brake on inflammatory responses: the role of glucocorticoids
    Hermoso, M
    Cidlowski, J
    [J]. IUBMB LIFE, 2003, 55 (09) : 497 - 504
  • [18] Glucocorticoid receptor antagonism by cyproterone acetate and RU486
    Honer, C
    Nam, K
    Fink, C
    Marshall, P
    Ksander, G
    Chatelain, RE
    Cornell, W
    Steele, R
    Schweitzer, R
    Schumacher, C
    [J]. MOLECULAR PHARMACOLOGY, 2003, 63 (05) : 1012 - 1020
  • [19] JEFFREY JM, 1991, J MED CHEM, V34, P447
  • [20] Novel glucocorticoid receptor coactivator effector mechanisms
    Jenkins, BD
    Pullen, CB
    Darimont, BD
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2001, 12 (03) : 122 - 126